Treatment of rheumatoid arthritis-associated interstitial lung disease: A perspective review

Therapeutic Advances in Musculoskeletal Disease

Volumn 7, Issue 6, 2015, Pages 247-267

  Iqbal, Kundan ^a   Kelly, Clive ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

arthritis; fibrosis; joints; lungs; pulmonary; rheumatoid; therapy

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; PIRFENIDONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; HISTOPATHOLOGY; INCIDENCE; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; MORTALITY; OXYGEN THERAPY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING;

EID: 84946073267     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X15612250     Document Type: Review

References (199)

1. Agusti C. Xaubet A. Roca J. Agusti A. Rodriguez-Roisin R. (1992) Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up. Thorax 47: 1035–1040.
2. Airo P. Danieli E. Rossi M. Frassi M. Cavazzana I. Scarsi M. et al (2007) Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 25: 293–296.
3. American Thoracic Society/European Respiratory Society (2002) American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Resp Crit Care Med 165: 277–304.
4. Antoniou K. Mamoulaki M. Malagari K. Kritikos H. Bouros D. Siafakas N. et al (2007) Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 25: 23–28.
5. Assayag D. Elicker B. Urbania T. Colby T. Kang B. Ryu J. et al (2014) Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 270: 583–588.
6. Atkins S. Turesson C. Myers J. Tazelaar H. Ryu J. Matteson E. et al (2006) Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis–associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 54: 635–641.
7. Aubart F. Crestani B. Nicaise-Roland P. Tubach F. Bollet C. Dawidowicz K. et al (2011) High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 38: 979–982.
8. Ayhan-Ardic F. Oken O. Yorgancioglu Z. Ustun N. Gokharman F. (2006) Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol 25: 213–218.
9. Bargagli E. Galeazzi M. Rottoli P. (2004) Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Resp J 24: 708.
10. Barskova T. Gargani L. Guiducci S. Randone S. Bruni C. Carnesecchi G. et al (2013) Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. Ann Rheum Dis 72: 390–395.
11. Bartels C. Bell C. Shinki K. Rosenthal A. Bridges A. (2010) Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20 years. Rheumatology (Oxford) 49: 1670–1675.
12. Becerra G. Cambridge M. (2013) Safety and efficacy of rituximab in patients with rheumatoid arthritis and lung involvement. Ann Rheum Dis 72 450.
13. Biederer J. Schnabel A. Muhle C. Gross W. Heller M. Reuter M. (2004) Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol 14: 272–280.
14. Bonella F. Costabel U. (2014) Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med 35: 181–200.
15. Bongartz T. Cantaert T. Atkins S. Harle P. Myers J. Turesson C. et al (2007) Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 46: 70–75.
16. Bongartz T. Nannini C. Medina-Velasquez Y. Achenbach S. Crowson C. Ryu J. et al (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62: 1583–1591.
17. Bosello S. de Luca G. Rucco M. Berardi G. Falcione M. Danza F. et al (2015) Long-Term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 44: 428–436.
18. Braun-Moscovici Y. Butbul-Aviel Y. Guralnik L. Toledano K. Markovits D. Rozin A. et al (2013) Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatology Int 33: 1495–1504.
19. Brown K. (2007) Rheumatoid lung disease. Proc Am Thorac Soc 4: 443–448.
20. Cavagna L. Monti S. Grosso V. Boffini N. Scorletti E. Crepaldi G. et al (2013) The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. BioMed Res Int 2013: 13.
21. Chan E. Chapman K. Kelly C. (2013) Interstitial lung disease in rheumatoid arthritis: a review. Arthritis Research Topical Reviews Series 7: 1–4.
22. Charles P. Sweatman M. Markwick J. Maini R. (1991) Hla-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. Dis Markers 9: 97–101.
23. Chen J. Doyle T. Liu Y. Aggarwal R. Wang X. Shi Y. et al (2015) Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 67: 28–38.
24. Chikura B. Sathi N. Lane S. Dawson J. (2008) Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology 47: 1647–1650.
25. Clozel M. Salloukh H. (2005) Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 37: 2–12.
26. Cogliati C. Antivalle M. Torzillo D. Birocchi S. Norsa A. Bianco R. et al (2014) Standard and pocket-size lung ultrasound devices can detect interstitial lung disease in rheumatoid arthritis patients. Rheumatology (Oxford) 53: 1497–1503.
27. Conway R. Low C. Coughlan R. O'Donnell M. Carey J. (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 66: 803–812.
28. Cottin V. (2013) The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res 14(Suppl. 1): S5.
29. Daniels C. Lasky J. Limper A. Mieras K. Gabor E. Schroeder D. (2010) Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 181: 604–610.
30. Daoussis D. Liossis S. Tsamandas A. Kalogeropoulou C. Kazantzi A. Sirinian C. et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49: 271–280.
31. Daoussis D. Liossis S. Tsamandas A. Kalogeropoulou C. Paliogianni F. Sirinian C. et al (2012) Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 30: S17–S22.
32. Dascalu C. Mrejen-Shakin K. Bandagi S. (2010) Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J Clin Rheumatol 16: 172–174.
33. Dass S. Atzeni F. Vital E. Bingham S. Buch M. Beirne P. et al (2011) Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease. Ann Rheum Dis 70: 71.
34. Dawson J. Fewins H. Desmond J. Lynch M. Graham D. (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56: 622–627.
35. Dawson J. Fewins H. Desmond J. Lynch M. Graham D. (2002) Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 61: 517–521.
36. Delle Sedie A. Doveri M. Frassi F. Gargani L. D'Errico G. Pepe P. et al (2010) Ultrasound lung comets in systemic sclerosis: a useful tool to detect lung interstitial fibrosis. Clin Exp Rheumatol 28: S54.
37. Demedts M. Behr J. Buhl R. Costabel U. Dekhuijzen R. Jansen H. et al (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353: 2229–2242.
38. Dhooria S. Agarwal R. Gupta D. (2015) Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases? Lung India 32: 4–5.
39. Dias O. Pereira D. Baldi B. Costa A. Athanazio R. Kairalla R. et al (2014) Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. J Bras Pneumol 40: 77–81.
40. Dixon W. Abrahamowicz M. Beauchamp M. Ray D. Bernatsky S. Suissa S. et al (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis 71: 851–857.
41. Dixon W. Hyrich K. Watson K. Lunt M. Symmons D. (2010) Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 69: 1086–1091.
42. Doyle T. Lee J. Dellaripa P. Lederer J. Matteson E. Fischer A. et al (2014) A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest 145: 454–463.
43. Doyle T. Patel A. Hatabu H. Nishino M. Wu G. Osorio J. et al (2015) Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Resp Crit Care Med 191: 1403–1412.
44. Eyre S. Bowes J. Diogo D. Lee A. Barton A. Martin P. et al (2012) High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44: 1336–1340.
45. Fingerlin T. Murphy E. Zhang W. Peljto A. Brown K. Steele M. et al (2013) Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 45: 613–620.
46. Fischer A. Brown K. Du Bois R. Frankel S. Cosgrove G. Fernandez-Perez E. et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40: 640–646.
47. Fischer A. Solomon J. Du Bois R. Deane K. Olson A. Fernandez-Perez E. et al (2012) Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Resp Med 106: 1040–1047.
48. Flaherty K. Colby T. Travis W. Toews G. Mumford J. Murray S. et al (2003) Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular Disease. Am J Respir Crit Care Med 167: 1410–1415.
49. Furukawa H. Oka S. Shimada K. Rheumatoid Arthritis-Interstitial Lung Disease Study Consortium, Tsuchiya N. Tohma S. (2013) HlA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker? Ann Rheum Dis 72: 153–155.
50. Furukawa H. Oka S. Shimada K. Sugii S. Ohashi J. Matsui T. et al (2012) Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope. PloS ONE 7: e33133.
51. Furuya Y. Kuwana M. (2011) Effect of bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. J Rheumatol 38: 2186–2192.
52. Gabbay E. Tarala R. Will R. Carroll G. Adler B. Cameron D. et al (1997) Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 156: 528–535.
53. Gaffo A. Alarcón G. (2008) Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168: 1927–1928.
54. Giles J. Danoff S. Sokolove J. Wagner C. Winchester R. Pappas D. et al (2014) Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 73: 1487–1494.
55. Gizinski A. Mascolo M. Loucks J. Kervitsky A. Meehan R. Brown K. et al (2009) Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 28: 611–613.
56. Glaspole I. Hoy R. Ryan P. (2013) A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology (Oxford) 52: 2302–2304.
57. Gochuico B. Avila N. Chow C. Novero L. Wu H. Ren P. et al (2008) Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168: 159–166.
58. Goh N. Desai S. Veeraraghavan S. Hansell D. Copley S. Maher T. et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177: 1248–1254.
59. Habib H. Eisa A. Arafat W. Marie M. (2011) Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol 30: 217–221.
60. Hadjinicolaou A. Nisar M. Bhagat S. Parfrey H. Chilvers E. Ostor A. (2011) Non-infectious pulmonary complications of newer biological agents for rheumatic diseases–a systematic literature review. Rheumatology (Oxford) 50: 2297–2305.
61. Hadjinicolaou A. Nisar M. Parfrey H. Chilvers E. Östör A. (2012) Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology 51: 653–662.
62. Hagiwara K. Sato T. Takagi-Kobayashi S. Hasegawa S. Shigihara N. Akiyama O. (2007) Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 34: 1151–1154.
63. Hamblin M. Horton M. (2011) Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulmon Med 2011: 1–12.
64. Harlow L. Rosas I. Gochuico B. Mikuls T. Dellaripa P. Oddis C. et al (2013) Identification of citrullinated HSP 90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 65: 869–879.
65. Haroon M. McLaughlin P. Henry M. Harney S. (2011) Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 5: 299–304.
66. Hartung W. Maier J. Pfeifer M. Fleck M. (2012) Effective treatment of rheumatoid arthritis-associated interstitial lung disease by B-cell targeted therapy with rituximab. Case Reports Immunol 2012: 272303.
67. Herrinton L. Harrold L. Liu L. Raebel M. Taharka A. Winthrop K. et al (2013) Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf 22: 394–402.
68. Horai Y. Miyamura T. Shimada K. Takahama S. Minami R. Yamamoto M. et al (2012) Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther 37: 117–121.
69. Hubbard R. Venn A. (2002) The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 41: 676–679.
70. Hunninghake G. Zimmerman M. Schwartz D. King T. Lynch J. Hegele R. et al (2001) Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 164: 193–196.
71. Hyeon Ju J. Kim S. Lee J. Lee S. Yoo W. Choe J. et al (2007) Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 56: 2094–2096.
72. Inokuma S. (2011) Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. Exp Opin Drug Saf 10: 603–611.
73. Inui N. Enomoto N. Suda T. Kageyama Y. Watanabe H. Chida K. (2008) Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 41: 1074–1077.
74. Jani M. Hirani N. Matteson E. Dixon W. (2014) The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol 10: 284–294.
75. Johkoh T. Muller N. Cartier Y. Kavanagh P. Hartman T. Akira M. et al (1999) Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 211: 555–560.
76. Kabia A. Md Yusof M. Dass S. Vital E. Beirne P. Emery P. (2015) Efficacy and safety of rituximab in rheumatoid arthritis patients with concomitant interstitial lung disease: 10-year experience at single centre. Rheumatology 54: i86.
77. Kamata Y. Nara H. Kamimura T. Haneda K. Iwamoto M. Masuyama J. et al (2004) Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 43: 1201–1204.
78. Kawashiri S. Kawakami A. Sakamoto N. Ishimatsu Y. Eguchi K. (2012) A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 32: 4023–4026.
79. Kelly C. Chan E. Nisar M. Arthanari S. Woodhead F. Dawson J. et al (2013) Fri 0114 rheumatoid arthritis related interstitial lung disease – relevance of lung function tests and high resolution computed tomography in a large multi centre series. Ann Rheum Dis 72: A408–A409.
80. Kelly C. Saravanan V. (2008) Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Exp Opin Pharmacother 9: 3221–3230.
81. Kelly C. Saravanan V. Nisar M. Arthanari S. Woodhead F. Price-Forbes A. et al (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology 53: 1676–1682.
82. Khanna D. Saggar R. Mayes M. Abtin F. Clements P. Maranian P. et al (2011) A one-year, phase I/IIA, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 63: 3540–3546.
83. Kim E. Collard H. King T. (2009) Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 136: 1397–1405.
84. Kim E. Elicker B. Maldonado F. Webb W. Ryu J. van Uden J. et al (2010) Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Resp J 35: 1322–1328.
85. King T. Jr Behr J. Brown K. Du Bois R. Lancaster L. de Andrade J. et al (2008) Build-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177: 75–81.
86. King T. Jr Bradford W. Castro-Bernardini S. Fagan E. Glaspole I. Glassberg M. et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370: 2083–2092.
87. King T. Jr Brown K. Raghu G. Du Bois R. Lynch D. Martinez F. et al (2011) Build-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184: 92–99.
88. Kinoshita F. Hamano H. Harada H. Kinoshita T. Igishi T. Hagino H. et al (2004) Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 98: 1131–1137.
89. Klareskog L. Stolt P. Lundberg K. Källberg H. Bengtsson C. Grunewald J. et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54: 38–46.
90. Kocheril S. Appleton B. Somers E. Kazerooni E. Flaherty K. Martinez F. et al (2005) Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 53: 549–557.
91. Koduri G. Norton S. Young A. Cox N. Davies P. Devlin J. et al (2010) Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 49: 1483–1489.
92. Koike T. Harigai M. Inokuma S. Inoue K. Ishiguro N. Ryu J. et al (2009) Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36: 898–906.
93. Koike T. Harigai M. Ishiguro N. Inokuma S. Takei S. Takeuchi T. et al (2012) Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Modern Rheumatol 22: 498–508.
94. Komiya K. Ishii H. Fujita N. Oka H. Iwata A. Sonoda H. et al (2011) Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement. Intern Med 50: 749–751.
95. Kozo S. Yasunari M. Tsukasa O. Tomoya T. Haruhiko F. Kimitake T. et al (2013) Proteomics analysis of BALF in rheumatoid arthritis associated interstitial lung disease with usual interstitial pneumonia pattern, B67. Insights into Fibrosis from Translational Studies. Proc Am Thorac Soc 3: 467–471.
96. Kubo H. Nakayama K. Yanai M. Suzuki T. Yamaya M. Watanabe M. et al (2005) Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128: 1475–1482.
97. Lager J. Hilberg O. Lokke A. Bendstrup E. (2013) Severe interstitial lung disease following treatment with certolizumab pegol: a case report. Eur Respir Rev 22: 414–416.
98. Lake F. Proudman S. (2014) Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Semin Respir Crit Care Med 35: 222–238.
99. Lee H. Kim D. Yoo B. Seo J. Rho J. Colby T. et al (2005) Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 127: 2019–2027.
100. Legg K. (2010) Connective tissue diseases: bosentan treatment unable to alter the progression of interstitial lung disease in patients with SSC. Nat Rev Rheumatol 6: 309–309.
101. Lindsay K. Melsom R. Jacob B. Mestry N. (2006) Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 45: 1048–1049.
102. Lioté H. Lioté F. Séroussi B. Mayaud C. Cadranel J. (2010) Rituximab-induced lung disease: a systematic literature review. Eur Resp J 35: 681–687.
103. Makrygiannakis D. Hermansson M. Ulfgren A. Nicholas A. Zendman A. Eklund A. et al. (2008) Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 67: 1488–1492.
104. Martin N. Innes J. Lambert C. Turnbull C. Wallace W. (2007) Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol 34: 1934–1937.
105. Matteson E. Bongartz T. Ryu J. Crowson C. Hartman T. Dellaripa P. (2012) Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis 2: 53–58.
106. Mazzei M. Richeldi L. Collard H. (2015) Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 9: 121–129.
107. McGonagle D. Tan A. Madden J. Rawstron A. Rehman A. Emery P. et al. (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 47: 552–553.
108. Mera-Varela A. Perez-Pampin E. (2014) Abatacept therapy in rheumatoid arthritis with interstitial lung disease. J Clin Rheumatol 20: 445–446.
109. Michalski J. McCombs C. Scopelitis E. Biundo J. Jr Medsger T. Jr (1986) Alpha1-antitrypsin phenotypes, including m subtypes, in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis. Arthritis Rheum 29: 586–591.
110. Migita K. Nakamura T. Koga T. Eguchi K. (2010) HLA-DRB1 alleles and rheumatoid arthritis-related pulmonary fibrosis. J Rheumatol 37: 205–207.
111. Min J. Lee H. Lim H. Ahn M. Park K. Chung M. et al. (2011) Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 68: 1099–1109.
112. Mink S. Maycher B. (2012) Comparative manifestations and diagnostic accuracy of high-resolution computed tomography in usual interstitial pneumonia and nonspecific interstitial pneumonia. Curr Opin Pulm Med 18: 530–534.
113. Miura Y. Saito T. Fujita K. Tanaka T. Tsunoda Y. Azuma A. et al. (2014) Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 31: 235–238.
114. Moazedi-Fuerst F. Kielhauser S. Brickmann K. Tripolt N. Meilinger M. Lufti A. et al. (2015) Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. Clin Exp Rheumatol 33(Suppl. 91): S87–S91.
115. Moazedi-Fuerst F. Kielhauser S. Scheidl S. Tripolt N. Lutfi A. Yazdani-Biuki B. et al. (2014) Ultrasound screening for interstitial lung disease in rheumatoid arthritis. Clin Exp Rheumatol 32: 199–203.
116. Mohr M. Jacobi A. (2011) Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol 40: 400–401.
117. Mori S. Imamura F. Kiyofuji C. Sugimoto M. (2006) Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol 16: 251–255.
118. Mori S. Koga Y. Sugimoto M. (2012) Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Resp Med 106: 1591–1599.
119. Nagai S. Hamada K. Shigematsu M. Taniyama M. Yamauchi S. Izumi T. (2002) Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41: 1118–1123.
120. Nakamura Y. Suda T. Kaida Y. Kono M. Hozumi H. Hashimoto D. et al. (2012) Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. Resp Med 106: 1164–1169.
121. Nakashita T. Ando K. Kaneko N. Takahashi K. Motojima S. (2014) Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open 4: e005615.
122. Nannini C. West C. Erwin P. Matteson E. (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10: R124.
123. National Institute for Health and Care Excellence (2009) Rheumatoid Arthritis: The Management of Rheumatoid Arthritis in Adults. London: NICE.
124. National Institute of Health and Care Excellence (2013) Pirfenidone for Treating Idiopathic Pulmonary Fibrosis. NICE technology appraisal guidance TA282. London: NICE
125. Noth I. Anstrom K. Calvert S. De Andrade J. Flaherty K. Glazer C. et al. (2012) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186: 88–95.
126. O'Dwyer D. Armstrong M. Cooke G. Dodd J. Veale D. Donnelly S. (2013) Rheumatoid arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med 24: 597–603.
127. Oka S. Furukawa H. Shimada K. Hayakawa H. Fukui N. Tsuchiya N. et al. (2013) Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease. BMC Immunol 14: 9.
128. Okada Y. Wu D. Trynka G. Raj T. Terao C. Ikari K. et al. (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506: 376–381.
129. Olivas-Flores E. Bonilla-Lara D. Gamez-Nava J. Rocha-Muñoz A. Gonzalez-Lopez L. (2015) Interstitial lung disease in rheumatoid arthritis: current concepts in pathogenesis, diagnosis and therapeutics. World J Rheumatol 5: 1–22.
130. Ostor A. Chilvers E. Somerville M. Lim A. Lane S. Crisp A. et al. (2006) Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 33: 622–628.
131. Panopoulos S. Sfikakis P. (2011) Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulmon Med 17: 362–367.
132. Park J. Kim D. Park I. Jang S. Kitaichi M. Nicholson A. et al. (2007) Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175: 705–711.
133. Pearce F. Johnson S. Courtney P. (2012) Interstitial lung disease following certolizumab pegol. Rheumatology (Oxford) 51: 578–580.
134. Perez-Alvarez R. Perez-De-Lis M. Diaz-Lagares C. Pego-Reigosa J. Retamozo S. Bove A. et al. (2011) Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 41: 256–264.
135. Raghu G. Anstrom K. King T. Jr Lasky J. Martinez F. (2012) Prednisone, azathioprine, and n-acetylcysteine for pulmonary fibrosis. N Engl J Med 366: 1968–1977.
136. Raghu G. Depaso W. Cain K. Hammar S. Wetzel C. Dreis D. et al. (1991) Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144: 291–296.
137. Rajasekaran A. Shovlin D. Saravanan V. Lord P. Kelly C. (2006) Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol 33: 1250–1253.
138. Ramos-Casals M. Brito-Zeron P. Munoz S. Soria N. Galiana D. Bertolaccini L. et al. (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242–251.
139. Richardson C. Singer J. (2014) Lung transplantation for scleroderma-related lung disease. Curr Resp Care Rep 3: 79–87.
140. Richeldi L. (2013) Clinical trials of investigational agents for IPF: a review of a Cochrane report. Respir Res 14(Suppl. 1): S4.
141. Richeldi L. Costabel U. Selman M. Kim D. Hansell D. Nicholson A. et al. (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365: 1079–1087.
142. Richeldi L. Du Bois R. Raghu G. Azuma A. Brown K. Costabel U. et al. (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370: 2071–2082.
143. Richman N. Yazdany J. Graf J. Chernitskiy V. Imboden J. (2013) Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine 92: 92–97.
144. Romero F. Recuero S. Gomez-Seco J. Rodriguez-Nieto M. Presa T. Mahillo I. et al. (2013) Safety and clinical response to rituximab in patients with connective tissue disease-associated interstitial lung disease: preliminary results. Ann Rheum Dis 71: 1496–1499.
145. Rosas I. Richards T. Konishi K. Zhang Y. Gibson K. Lokshin A. et al. (2008) MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 5: e93.
146. Roubille C. Haraoui B. (2014) Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 43: 613–626.
147. Saag K. Kolluri S. Koehnke R. Georgou T. Rachow J. Hunninghake G. et al. (1996) Rheumatoid arthritis lung disease. determinants of radiographic and physiologic abnormalities. Arthritis Rheum 39: 1711–1719.
148. Sabnani I. Zucker M. Rosenstein E. Baran D. Arroyo L. Tsang P. et al. (2009) A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology 48: 49–52.
149. Saketkoo L. Espinoza L. (2008) Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med 168: 1718–1719.
150. Saketkoo L. Espinoza L. (2009) Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 337: 329–335.
151. Salliot C. Van der Heijde D. (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68: 1100–1104.
152. Sathi N. Chikura B. Kaushik V. Wiswell R. Dawson J. (2012) How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol 31: 79–83.
153. Sathi N. Urwin T. Desmond S. Dawson J. (2011) Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease. Rheumatology 50: 620.
154. Savage R. Highton J. Boyd I. Chapman P. (2006) Pneumonitis associated with leflunomide: a profile of New Zealand and Australian Reports. Intern Med J 36: 162–169.
155. Sawada T. Inokuma S. Sato T. Otsuka T. Saeki Y. Takeuchi T. et al. (2009) Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 48: 1069–1072.
156. Schachna L. Medsger T. Jr Dauber J. Wigley F. Braunstein N. White B. et al. (2006) Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 54: 3954–3961.
157. Schoe A. Van Der Laan-Baalbergen N. Huizinga T. Breedveld F. Van Laar J. (2006) Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum 55: 157–159.
158. Schwarz M. King T. (2010) Interstitial Lung Disease. People's Medical Publishing House. Available at: www.axon.es/Axon/LibroFicha.asp?Libro=81891
159. Seibold J. Denton C. Furst D. Guillevin L. Rubin L. Wells A. et al. (2010) Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 62: 2101–2108.
160. Sharyn L. Michael B. David M. Susan J. Sujal R. Roland M. et al. (2001) Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 221: 600–605.
161. Silva C. Muller N. Hansell D. Lee K. Nicholson A. Wells A. (2008) Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology 247: 251–259.
162. Song J. Lee H. Lee C. Chae E. Jang S. Colby T. et al. (2013) Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 30: 103–112.
163. Soubrier M. Jeannin G. Kemeny J. Tournadre A. Caillot N. Caillaud D. et al. (2008) Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 75: 362–365.
164. Spagnolo P. Grunewald J. Du Bois R. (2014) Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Resp Med 2: 416–428.
165. Sperandeo M. Varriale A. Sperandeo G. Filabozzi P. Piattelli M. Carnevale V. et al. (2009) Transthoracic ultrasound in the evaluation of pulmonary fibrosis: our experience. Ultrasound Med Biol 35: 723–729.
166. Stahl E. Raychaudhuri S. Remmers E. Xie G. Eyre S. Thomson B. et al. (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42: 508–514.
167. Sugiyama Y. Ohno S. Kano S. Maeda H. Kitamura S. (1994) Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. Intern Med 33: 612–614.
168. Suissa S. Hudson M. Ernst P. (2006) Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 54: 1435–1439.
169. Sumida H. Asano Y. Tamaki Z. Aozasa N. Taniguchi T. Takahashi T. et al. (2014) Successful Experience of Rituximab Therapy for Systemic Sclerosis-Associated Interstitial Lung Disease with Concomitant Systemic Lupus Erythematosus. J Dermatol 41: 418–420.
170. Suwa A. Hirakata M. Satoh S. Mimori T. Utsumi K. Inada S. (1998) Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with IV cyclophosphamide therapy. Clin Exp Rheumatol 17: 355–358.
171. Swigris J. Olson A. Fischer A. Lynch D. Cosgrove G. Frankel S. et al. (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130: 30–36.
172. Takeuchi T. Tatsuki Y. Nogami Y. Ishiguro N. Tanaka Y. Yamanaka H. et al. (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189–194.
173. Taki H. Kawagishi Y. Shinoda K. Hounoki H. Ogawa R. Sugiyama E. et al. (2009) Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int 30: 275–276.
174. Tanaka N. Kim J. Newell J. Brown K. Cool C. Meehan R. et al. (2004) Rheumatoid arthritis-related lung diseases: CT findings. Radiology 232: 81–91.
175. Tardella M. Gutierrez M. Salaffi F. Carotti M. Ariani A. Bertolazzi C. et al. (2012) Ultrasound in the assessment of pulmonary fibrosis in connective tissue disorders: correlation with high-resolution computed tomography. J Rheumatol 39: 1641–1647.
176. Tashkin D. Elashoff R. Clements P. Goldin J. Roth M. Furst D. et al. (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354: 2655–2666.
177. Tashkin D. Elashoff R. Clements P. Roth M. Furst D. Silver R. et al. (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176: 1026–1034.
178. The Idiopathic Pulmonary Fibrosis Clinical Research Network (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370: 2093–2101.
179. Tournadre A. Ledoux-Eberst J. Poujol D. Dubost J.J. Ristori J.M. Soubrier M. (2008) Exacerbation of interstitial lung disease during etanercept therapy: two cases. Joint Bone Spine 75: 215–218.
180. Tsuchiya Y. Takayanagi N. Sugiura H. Miyahara Y. Tokunaga D. Kawabata Y. et al. (2011) Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37: 1411–1417.
181. Turesson C. Jacobsson L. Sturfelt G. Matteson E. Mathsson L. Ronnelid J. (2007) Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66: 59–64.
182. Tzouvelekis A. Galanopoulos N. Bouros E. Kolios G. Zacharis G. Ntolios P. et al. (2012) Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med 2012: 7.
183. Udwadia Z. Mullerpattan J. Balakrishnan C. Richeldi L. (2015) Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India 32: 50–52.
184. Vassallo R. Matteson E. Thomas C. Jr (2002) Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-α inhibition. Chest 122: 1093–1096.
185. Wada T. Akiyama Y. Yokota K. Sato K. Funakubo Y. Mimura T. (2012) [A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept]. Nihon Rinsho Meneki Gakkai Kaishi 35: 433–438.
186. Wang Y. Xu S. Xu J. Ding C. (2011) Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease. Clin Med Insights Case Rep 4: 49–52.
187. Wells A. Hirani N. (2008) Interstitial lung disease guideline. Thorax 63: v1–v58.
188. Wells A. Ward S. (2014) Pulmonary function tests in idiopathic pulmonary fibrosis. In: Ed. Meyer K. Nathan S. (eds), Idiopathic Pulmonary Fibrosis, Vol. 9. Humana Press, pp. 103–121. Available at: link.springer.com/content/pdf/10.1007/978-1-62703-682-5_6.pdf
189. Wendling D. Vidon C. Godfrin-Valnet M. Rival G. Guillot X. Prati C. (2013) Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine 80: 670–671.
190. Xaubet A. Serrano-Mollar A. Ancochea J. (2014) Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Exp Opin Pharmacother 15: 275–281.
191. Yamazaki H. Isogai S. Sakurai T. Nagasaka K. (2010) A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis. Mod Rheumatol 20: 518–521.
192. Yazdani A. Singer L. Strand V. Gelber A. Williams L. Mittoo S. (2014) Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 33: 514–520.
193. Yiannopoulos G. Pastromas V. Antonopoulos I. Katsiberis G. Kalliolias G. Liossis S. et al. (2007) Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27: 357–361.
194. Yin Y. Liang D. Zhao L. Li Y. Liu W. Ren Y. et al. (2014) Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One 9: e92449.
195. Yoo W. (2012) Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 32: 795–798.
196. Yoshinouchi T. Ohtsuki Y. Fujita J. Yamadori I. Bandoh S. Ishida T. et al. (2005) Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 26: 121–125.
197. Young A. Koduri G. Batley M. Kulinskaya E. Gough A. Norton S. et al. (2007) Mortality in rheumatoid arthritis. increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46: 350–357.
198. Ytterberg A. Joshua V. Reynisdottir G. Tarasova N. Rutishauser D. Ossipova E. et al. (2014) Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis 74: 1772–1777.
199. Zhu J. Zhou Y. Chen X. Li J. (2014) A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 41: 1282–1289.